Dyadic and Proliant Announce Commercial Launch of Recombinant Human Albumin AlbuFree DX

Dyadic Applied BioSolutions and Proliant Health & Biologicals have launched AlbuFree DX, a recombinant human albumin product produced using Dyadic's filamentous fungal expression technology. The launch underscores Dyadic's strategy to prioritize recombinant protein products with clear commercial pathways and established end markets. Dyadic will receive a share of profits from Proliant's commercial sales of recombinant human albumin products. This marks the first major commercial step in Dyadic's portfolio of market-specific proteins and represents an important milestone in converting licensed programs into recurring revenue streams.